During the recent session, Seres Therapeutics Inc (NASDAQ:MCRB)’s traded shares were 0.66 million, with the beta value of the company hitting 2.25. At the last check today, the stock’s price was $0.75, reflecting an intraday loss of -0.68% or -$0.01. The 52-week high for the MCRB share is $6.87, that puts it down -816.0 from that peak though still a striking 5.33% gain since the share price plummeted to a 52-week low of $0.71. The company’s market capitalization is $113.26M, and the average intraday trading volume over the past 10 days was 3.27 million shares, and the average trade volume was 4.75 million shares over the past three months.
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Seres Therapeutics Inc (MCRB) registered a -0.68% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.68% in intraday trading to $0.75, hitting a weekly high. The stock’s 5-day price performance is -3.11%, and it has moved by -25.74% in 30 days. Based on these gigs, the overall price performance for the year is -87.07%. The short interest in Seres Therapeutics Inc (NASDAQ:MCRB) is 18.4 million shares and it means that shorts have 3.79 day(s) to cover.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Statistics show that Seres Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Seres Therapeutics Inc (MCRB) shares have gone down -62.50% during the last six months, with a year-to-date growth rate less than the industry average at -29.21% against 13.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 40.40% this quarter and then drop -186.10% in the quarter after that. In the rating firms’ projections, revenue will decrease -98.90% compared to the previous financial year.
Revenue for the current quarter is expected to be $250k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $250k by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.38 million and $126.47 million respectively. In this case, analysts expect current quarter sales to shrink by -81.90% and then drop by -99.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.22%. While earnings are projected to return -20.06% in 2024.
MCRB Dividends
Seres Therapeutics Inc is due to release its next quarterly earnings between May 07 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
Seres Therapeutics Inc insiders own 5.68% of total outstanding shares while institutional holders control 59.48%, with the float percentage being 63.06%. Flagship Pioneering Inc. is the largest shareholder of the company, while 136 institutions own stock in it. As of Dec 30, 2023, the company held over 23.12 million shares (or 15.31% of all shares), a total value of $17.16 million in shares.
The next largest institutional holding, with 19.39 million shares, is of FMR, LLC’s that is approximately 12.84% of outstanding shares. At the market price on Dec 30, 2023, these shares were valued at $14.4 million.
Also, the Mutual Funds coming in first place with the largest holdings of Seres Therapeutics Inc (MCRB) shares are Federated Hermes Kaufmann Fund and Fidelity Growth Company Fund. Data provided on Oct 30, 2023 indicates that Federated Hermes Kaufmann Fund owns about 6.01 million shares. This amounts to just over 3.98 percent of the company’s overall shares, with a $4.46 million market value. The same data shows that the other fund manager holds slightly less at 5.85 million, or about 3.87% of the stock, which is worth about $4.34 million.
